NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from New York State to launch its ThyraMIR diagnostic assay on formalin-fixed, paraffin-embedded tissue samples from thyroid nodules.
According to Interpace, its ThyraMIR assay is now the only molecular test approved to be used on indeterminate thyroid nodule samples presented through fine needle aspirates in Asuragen's RNARetain cellular preservation device, cytology slides, and FFPE fixation in the State of New York.
Interpace's ThyraMIR panel is a microRNA gene expression classifier designed to help diagnose nodules with indeterminate cytology. In combination with New York State's previous approval of the firm's ThyGeNext platform, Interpace said that physicians and patients will have increased access to its thyroid product suite across several specimen types.
"With this increased convenience factor, we can now provide our thyroid molecular testing services to an even broader customer base," Interpace Diagnostics CEO and President Jack Stover said in a statement.
In January, Interpace signed an agreement with the University of Maryland Medical System to provide UMMS physicians with access to ThyGeNext, ThyraMIR, and PancraGen diagnostic tests.